Advanced search
Publication Cover
Leukemia & Lymphoma Volume 5, 1991 - Issue sup1
Submit an article Journal homepage
18
Views
80
CrossRef citations to date
0
Altmetric
Original Article

2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia

A. Saven Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, Division of Hematology/Oncology, La Jolla, California
,
C. J. Carrera Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, Division of Hematology/Oncology, La Jolla, California
,
D. A. Carson Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, Division of Hematology/Oncology, La Jolla, California
,
E. Beutler Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, Division of Hematology/Oncology, La Jolla, California
&
L. D. Piro Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, Division of Hematology/Oncology, La Jolla, California
Pages 133-138 | Published online: 01 Jul 2009

References

  • Foon K. A., Rai K. R., Gayle P. Chronic lymphocytic leukemia: New insights into biology and therapy. Annals of Internal Medicine 1990; 113: 525–39
  • Raphael B., Anderson J. W., Silber R. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an ECOG randomized clinical trial. Journal of Clinical Oncology 1991; 9: 770–76
  • Kempin S., Lee B. J., Thaler H. T., Koziner B., Hecht S., Gee T., Arlin Z., Little C., Straus D., Reich L., Phillips E., Al-Mondhiry H., Dowling M., Mayer K., Clarkson B. The M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan and prednisone). Blood 1982; 60: 1110–21
  • Dillman R. O., Mick R., McIntyre O. R. Pentostatin in chronic lymphocytic leukemia: A phase II trial of cancer and leukemia group B. Journal of Clinical Oncology 1989; 7: 433–38
  • Ho A. D., Thaler J., Stryckmans P. Pentostatin in resistant chronic lymphocytic leukemia. A phase II trial of the European organization for research and treatment of cancer. Proceedings of the American Society of Clinical Oncology 1990; 9: 206
  • Keating M. J., Kantarjian H., Talpaz M. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
  • Keating M. J. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Seminars in Oncology 1990; 17: 49–62
  • Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–43
  • Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-chloro-deoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–73
  • Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. Phase II trial update of 2-chlorodeoxyadenosine treatment of advanced chronic lymphocytic leukemia. Proceedings of the American Society of Clinical Oncology 1990; 9: 212
  • Position Paper. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging and response criteria (International Workshop on chronic lymphocytic leukemia). Annals of Internal Medicine 1989; 110: 236
  • Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. American Journal of Hematology 1988; 29: 152–63
  • Carson D. A., Wasson D. B., Beutler E. Antileukemia and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proceedings of the National Academy of Sciences of the United states of America 1981; 81: 2232–36
  • Oken M. M., Creech L. H., Tormey D. C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5: 649–55
  • McMillan R., Tani P., Millard F., Berchtold P., Renshaw L., Woods V. L. Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood 1987; 70: 1040–45
  • Urba W. J., Baseler M. W., Kopp W. C. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989; 73: 38–46
  • Kraut E. H., Neff J. C., Bouroncle B. A., Gochnour D., Grever M. R. Immunosuppressive effects of pentostatin. Journal of Clinical Oncology 1990; 8: 848–55

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.